CYTK vs RYTM: stock comparison and AI forecast
Cytokinetics Inc (CYTK) and Rhythm Pharmaceuticals, Inc. (RYTM) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CYTK Cytokinetics Inc
- Price
- $55.55 -25.2% · 6M
- Market Cap
- $7.72B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
RYTM Rhythm Pharmaceuticals, Inc.
- Price
- $110.68 +14.6% · 6M
- Market Cap
- $5.95B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- CYTK is 1.3 times larger than RYTM by market capitalization ($7.72B against $5.95B).
- Over the last six months RYTM returned +14.6% and CYTK -25.2%.
- RYTM turns -69.0% of its revenue into net income, against -946.7% for CYTK.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CYTK | RYTM |
|---|---|---|
| Market Cap | $7.72B | $5.95B |
| P/B Ratio | – | 67.53x |
| EPS | $-6.05 | $-2.88 |
| Book Value/Share | – | $1.28 |
| Revenue/Share | $0.83 | $4.08 |
| FCF/Share | $-4.23 | – |
Profitability & Margins
| Metric | CYTK | RYTM |
|---|---|---|
| ROE | – | -220.3% |
| ROA | – | -43.7% |
| ROIC | – | -64.1% |
| Gross Margin | – | 88.2% |
| Operating Margin | -915.8% | -66.7% |
| Net Margin | -946.7% | -69.0% |
| EBT Margin | -915.8% | -68.5% |
| Tax Rate | – | -0.8% |
Financial Health
| Metric | CYTK | RYTM |
|---|---|---|
| Current Ratio | 3.36x | 2.78x |
| Quick Ratio | 3.36x | 2.57x |
| D/E Ratio | – | 2.75x |
| Financial Leverage | – | 5.04x |
| Interest Coverage | -13.3x | -29.4x |
| Working Capital | $834M | $268M |
Cash Flow
| Metric | CYTK | RYTM |
|---|---|---|
| Operating Cash Flow | -$572M | -$82M |
| Free Cash Flow | -$589M | – |
| Capital Spending | -$17M | – |
| FCF/Sales | -512.4% | – |
| CapEx/Sales | 14.5% | – |
Operational Efficiency
| Metric | CYTK | RYTM |
|---|---|---|
| Asset Turnover | – | 0.63x |
| Receivables Turnover | 3.4x | 7.2x |
| Inventory Turnover | – | 1.1x |
| Fixed Assets Turnover | 1.5x | 493.4x |
| Days Sales Outstanding | 108 days | 51 days |
| Days Inventory | – | 344 days |
| Payables Period | – | 118 days |
| Cash Conversion Cycle | – | 277 days |
Income Statement
| Metric | CYTK | RYTM |
|---|---|---|
| Total Revenue | $115M | $281M |
| Operating Income | -$708M | -$187M |
| Net Income | -$732M | -$194M |
| R&D Expense | $397M | $180M |
| SG&A Expense | – | $255M |
| Cost of Goods Sold | – | $33M |
Dividend & Shareholder Information
| Metric | CYTK | RYTM |
|---|---|---|
| Shares Outstanding | 139M | 69M |
CYTK vs RYTM: stock comparison and AI forecast
Which is bigger, CYTK or RYTM?
CYTK is 1.3 times larger than RYTM by market capitalization ($7.72B against $5.95B).
Which stock performed better over the last six months, CYTK or RYTM?
Over the last six months RYTM returned +14.6% and CYTK -25.2%.
Which one does Intratio's AI model rank higher, CYTK or RYTM?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.